Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
407,321

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Conmed (CNMD) Q3 Earnings Expected to Decline

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HSIC or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Retain CONMED (CNMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Conmed (CNMD) Down 4.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HSIC vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

HSIC vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

CONMED's (CNMD) Q2 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

CONMED (CNMD) witnesses revenue uptick in both of its segments during Q2 despite continued pandemic-led business disruptions.

Conmed (CNMD) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 14.52% and 2.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LH vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

LH vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

Align Technology (ALGN) Launches New Features in iTero Family

by Zacks Equity Research

Align Technology's (ALGN) iTero Workflow 2.0 software and iTero Element 5D Imaging system auto-upload functionality to drive innovation in digital orthodontics and restorative dentistry.

Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival

by Zacks Equity Research

Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.

Henry Schein (HSIC) Clinches HHS Deal for COVID-19 Supplies

by Zacks Equity Research

Henry Schein (HSIC) to extend effective inventory management and extensive logistical support for PPE and COVID related products within the spectrum of U.S. health care.

Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe

by Zacks Equity Research

These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.

Why Is Conmed (CNMD) Down 3.9% Since Last Earnings Report?

by Zacks Equity Research

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HSIC vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.

Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.

Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up

by Zacks Equity Research

Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.

IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up

by Zacks Equity Research

IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.

Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.

CONMED (CNMD) Surges 4.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

CONMED (CNMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.